STUTTGART, Germany I June 28, 2025 I Vectorized antibodies obtained by in vivo expression of DNA or RNA are an emerging drug modality with potential to overcome several of the limitations of passive immunotherapy with antibodies produced ex vivo. La Merie Publishing released a new report about gene therapy technologies...
Innovation fuels the biologics market growth of therapeutic antibodies and proteins in 2024
The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 09, 2025 I La Merie Publishing announced the release of its newest biologics market report for the calendar year 2024...
Outstanding antitumor activity of first-in-class and so far best-in-class PD-1xVEGF bispecific antibody opens up plenty of opportunities for business deals and better followers
STUTTGART, Germany I February 19, 2025 I La Merie Publishing released its newest report with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective as...
Degrader-Antibody Conjugates: an emerging novel drug modality to address undruggable targets
STUTTGART, Germany I September 04, 2024 I La Merie Publishing released its newest report with a landscape description and analysis of degrader-antibody conjugate (DAC) stakeholders, platform technologies, development and discovery pipelines and partnering deals from an industry perspective as of September 2024: Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders,...
2023 Global Biologics Sales exceeding US$ 300 bln for the first time
The report covers 2023 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 08, 2024 I La Merie Publishing released the new report with sales data of recombinant biologics, biosimilars and novel biologic...
Sales of Therapeutic Antibodies and Proteins in 2022 close to US$ 300 bln with Antibodies contributing more than 80%
BARCELONA, Spain I March 08, 2023 I La Merie Publishing released the 17th edition of its report series about sales of recombinant biologics. The report 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...
Chimeric Antigen Receptor Macrophages (CAR-M): an emerging technology with promise to improve efficacy and safety of tumor immunotherapy
BARCELONA, Spain I February 07, 2023 I La Merie Publishing released today its newest report entitled “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing”. This report provides a landscape description and analysis of the emerging technology of Chimeric Antigen Receptor Macrophages (CAR-M) from an...
Emerging RNA-Targeted Drug Modalities Open the Door for Novel Treatments
BARCELONA, Spain I November 13, 2022 I La Merie Publishing released today its newest report entitled “RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry...
Compelling novel cancer targets with promise of low on-target, off-tumor toxicity
BARCELONA, Spain I July 6, 2022 I La Merie Publishing released today a report bundle entitled “Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report bundle includes four reports about novel cancer targets which...
GPRC5D-Targeted drug modalities: a chance for cure of multiple myeloma?
BARCELONA, Spain I July 1, 2022 I La Merie Publishing released today its newest report entitled “GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report evaluates G-protein–coupled receptor family C group 5 member D (GPRC5D) from an industry perspective for...